CRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings Results, Misses Expectations By $0.11 EPS

CRISPR Therapeutics (NASDAQ:CRSP) posted its quarterly earnings data on Monday. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.11), FiscalAI reports. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The firm had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million.

CRISPR Therapeutics Trading Down 2.8%

CRSP stock traded down $1.43 during midday trading on Monday, reaching $49.99. The company’s stock had a trading volume of 1,019,604 shares, compared to its average volume of 1,723,191. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $64.74. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -10.50 and a beta of 1.76. The stock has a fifty day simple moving average of $54.19 and a two-hundred day simple moving average of $52.92. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 47,837 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $49.78, for a total value of $2,381,325.86. Following the completion of the sale, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at $15,526,332.22. The trade was a 13.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of the company’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the completion of the transaction, the director owned 16,637 shares in the company, valued at $949,806.33. This represents a 45.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,558 shares of company stock valued at $4,881,663 over the last ninety days. Company insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the topic of several recent analyst reports. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Monday, September 28th. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. UBS Group began coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They issued a “neutral” rating and a $52.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.